Vanguard Group’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,922,809
| Closed | -$1.59M | – | 4307 |
|
|
2025
Q1 | $1.59M | Hold |
1,922,809
| – | – | ﹤0.01% | 3567 |
|
|
2024
Q4 | $1.83M | Hold |
1,922,809
| – | – | ﹤0.01% | 3587 |
|
|
2024
Q3 | $1.92M | Hold |
1,922,809
| – | – | ﹤0.01% | 3568 |
|
|
2024
Q2 | $2.38M | Sell |
1,922,809
-25,786
| -1% | -$26.3K | ﹤0.01% | 3500 |
|
|
2024
Q1 | $2.53M | Buy |
1,948,595
+247,918
| +15% | +$283K | ﹤0.01% | 3516 |
|
|
2023
Q4 | $2.13M | Buy |
1,700,677
+12,312
| +0.7% | +$13.6K | ﹤0.01% | 3583 |
|
|
2023
Q3 | $2.19M | Buy |
1,688,365
+89,000
| +6% | +$144K | ﹤0.01% | 3550 |
|
|
2023
Q2 | $2.75M | Buy |
1,599,365
+96,549
| +6% | +$153K | ﹤0.01% | 3562 |
|
|
2023
Q1 | $2.19M | Sell |
1,502,816
-2,106
| -0.1% | -$4.04K | ﹤0.01% | 3636 |
|
|
2022
Q4 | $2.44M | Buy |
1,504,922
+2,338
| +0.2% | +$5.38K | ﹤0.01% | 3594 |
|
|
2022
Q3 | $5.03M | Sell |
1,502,584
-307,087
| -17% | -$1.39M | ﹤0.01% | 3327 |
|
|
2022
Q2 | $6.59M | Sell |
1,809,671
-791,820
| -30% | -$3.59M | ﹤0.01% | 3223 |
|
|
2022
Q1 | $18.8M | Sell |
2,601,491
-790,825
| -23% | -$6.74M | ﹤0.01% | 2813 |
|
|
2021
Q4 | $46.1M | Buy |
3,392,316
+58,595
| +2% | +$917K | ﹤0.01% | 2397 |
|
|
2021
Q3 | $69.9M | Buy |
3,333,721
+373,518
| +13% | +$8.02M | ﹤0.01% | 2177 |
|
|
2021
Q2 | $70.9M | Buy |
2,960,203
+1,502,911
| +103% | +$38M | ﹤0.01% | 2183 |
|
|
2021
Q1 | $42.7M | Buy |
1,457,292
+38,005
| +3% | +$1.11M | ﹤0.01% | 2402 |
|
|
2020
Q4 | $42.4M | Buy |
+1,419,287
| New | +$44.5M | ﹤0.01% | 2286 |
|
Vanguard Group's KRON Position: Q2 2025 in Review
Vanguard Group sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 1,922,809 shares — an estimated $1.59M sold.
Vanguard Group first reported a position in KRON in Q4 2020 and held it in 18 quarters. The position peaked at $70.9M in Q2 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Vanguard Group reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Vanguard Group sold 1,922,809 Kronos Bio shares in Q2 2025, an estimated $1.59M.
- Vanguard Group first reported a position in Kronos Bio in Q4 2020 and held it in 18 quarters.
- Vanguard Group's Kronos Bio position peaked at $70.9M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.